Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function
Epilepsy & Behavior · 2023
DOI: 10.1016/j.yebeh.2023.109453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2023. Verfasst von Jon Davis Perkins und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hamad Medical Corporation, Doha, Qatar; PMARC, University of Edinburgh, Edinburgh. UK. Electronic address: JPerkins@hamad.qa. Hauptthemen laut MEDLINE: Anticonvulsants, Piracetam. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hamad Medical Corporation.
Abstract (Originalsprache)
OBJECTIVE: Cognitive impairment is a potential drawback of antiseizure medications. This study aimed to evaluate the impact of different levetiracetam drug regimens on cognitive function. METHODS: A retrospective analysis identified 221 patients diagnosed with seizures who underwent cognitive screening. Patients were categorized into four groups: no medications, non-levetiracetam medications, high and low dose levetiracetam. Composite scores determined low and high levetiracetam groups whereby one point was added for each increment in dosage, duration since uptake, and concurrent anti-seizure medication. Variables known to affect cognition were recorded and classified as demographic, seizure-related, diagnosis-related, and psychopathology. Logistic regression was used to identify variables associated with cognitive scores below cut-off. RESULTS: Multivariable analysis found being male, non-active in the community, less than 12 years of education, left temporal lobe epilepsy, high seizure frequency, and depression were associated with poor cognitive performance. In a final regression analysis, the high levetiracetam group exhibited a 4.5-fold higher likelihood of scoring below cut-off than the medication-free group (OR 4.5, CI 1.5-13.6, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hamad Medical Corporation, Doha, Qatar; PMARC, University of Edinburgh, Edinburgh. UK. Electronic address: JPerkins@hamad.qa.
- Hamad Medical Corporation, Doha, Qatar.
- Greater Los Angeles VA Medical Center, Los Angeles, CA, USA; David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
- Hamad Medical Corporation, Doha, Qatar; Weill Cornell Medicine, Qatar, Education City, Doha, Qatar.
Förderung
- Hamad Medical Corporation
Zitieren
APA
Perkins, J. D., Abdelmoneim, M. S., Wilkins, S. S., Kamran, S., Mesraoua, B., Melikyan, G., Alrabi, A., El-Bardissy, A., Elalamy, O., & Al Hail, H. J. (2023). Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2023.109453
Vancouver
Perkins JD, Abdelmoneim MS, Wilkins SS, Kamran S, Mesraoua B, Melikyan G, et al. Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function. Epilepsy & Behavior. 2023. doi:10.1016/j.yebeh.2023.109453
BibTeX
@article{Perkins2023,
author = {Perkins, Jon Davis and Abdelmoneim, Mohamed S and Wilkins, Stacy Schantz and Kamran, Saadat and Mesraoua, Boulenouar and Melikyan, Gayane and Alrabi, Abdulraheem and El-Bardissy, Ahmed and Elalamy, Osama and Al Hail, Hassan Jassim},
title = {Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function},
journal = {Epilepsy & Behavior},
year = {2023},
doi = {10.1016/j.yebeh.2023.109453}
}
EUVIMED